Trial · NCT07389265
Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer
NCT07389265, Phase 3, Recruiting, University of Campania Luigi Vanvitelli
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer. Trials, record NCT07389265. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07389265
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer
- NCT number
- NCT07389265
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 480 participants, estimated
- Lead sponsor
- University of Campania Luigi Vanvitelli
- Conditions
- Metastatic Colorectal Cancer (mCRC)
- Interventions
- Erbitux (Cetuximab), Bevacizumab, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin), FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)
- First posted
- 2026-02-05
- Last updated
- 2026-02-05
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Response Rate (ORR) | From date of randomization until the date of first documented progression or date of death from any cause, or study completion whichever came first, assessed until 48 months. | The primary outcome is the Objective Response Rate, which will be evaluated according to the RECIST criteria 1.1. The study aims to determine if the continuous use of cetuximab in the experimental arm results in a superior Response Rate compared to the control arm with bevacizumab. |
| Secondary | Overall Survival (OS) | From randomization (Day 0) until death from any cause, assessed through study completion (up to 36 months of survival follow-up) | Time from randomization until death due to any cause. Patients alive at last follow-up will be censored at that date. |
| Secondary | Progression-Free Survival (PFS) | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months from last patient randomized. | Time from randomization until the date of first documented disease progression, as assessed by central independent review according to RECIST 1.1 criteria, or death from any cause, whichever occurs first. |
| Secondary | Safety Profile: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) | From first treatment administration until 30 days after the last dose. | The safety profile of the trial drugs as measured by the incidence of AEs, SAEs, clinical laboratory assessments, vital signs, physical examination, ECG parameters, and ECOG PS. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07389265
GET https://conductscience.org/api/trials/v1/NCT07389265/registered